Fundraising FoxNextech Invest — 2023 Investments
4 investments dated 2023 · listed companies and verified rows first · show all
Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.
BiotechSan Mateo, US
Gina Chapman(Executive Officer, Director)inAnup Radhakrishnan(Executive Officer)inCassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)
BoardAbraham Bassan(Director)
Co-investorsRed Tree VentureSamsara BioCapitalWellington ManagementAlly Bridge GroupJanus Henderson InvestorsPerceptive Xontogeny Venture+1 more
Flare Therapeutics develops small molecule medicines targeting transcription factors using a chemistry and proteomics platform that enables ligand discovery directly from cells.
AI & Machine LearningBiotechDeep TechHealthtech
Jim Audia(Executive Vice President, Drug Discovery and Early Development, and Founding Scientist)Jacob Stuckey(Senior Director, Biochemistry and Chemical Biology, and Founding Scientist)in
Co-investorsNexTech VenturesPfizer VenturesThird Rock VenturesPfizer Venture InvestmentsShangBay Capital LLCAgent Capital
A biotechnology company developing cancer therapies for patients with unmet medical needs.
BiotechHealthtech
Co-investorsAtlas VentureF-Prime CapitalEight Roads Ventures
Mariana Oncology, a Novartis company, develops precision radioligand therapies that deliver radioisotopes to diseased cells while limiting effects on healthy tissue.
BiotechHealthtechMedical Devices
Co-investorsAccess BiotechnologyAtlas VentureAccess IndustriesForbionRA Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.